The global cancer therapeutics and biotherapeutics market size is calculated at USD 210.73 billion in 2025 and is forecasted to reach around USD 440.59 billion by 2034, accelerating at a CAGR of 8.54% from 2025 to 2034. The North America market size surpassed USD 79.60 billion in 2024 and is expanding at a CAGR of 8.67% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Therapeutics and Biotherapeutics Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Therapeutics and Biotherapeutics Market, by Product Type
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Radiation Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Hormone Therapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Biotherapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Cancer Therapeutics and Biotherapeutics Market, by End User
9.1.1. Consumption (Sales)
9.1.1.1. Market Revenue and Forecast
9.1.2. Household
9.1.2.1. Market Revenue and Forecast
9.1.3. Hospital
9.1.3.1. Market Revenue and Forecast
10.1. Cancer Therapeutics and Biotherapeutics Market, by Application Type
10.1.1. Blood Cancer
10.1.1.1. Market Revenue and Forecast
10.1.2. Lung Cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Colorectal Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Prostate Cancer
10.1.4.1. Market Revenue and Forecast
10.1.5. Breast Cancer
10.1.5.1. Market Revenue and Forecast
10.1.6. Cervical Cancer
10.1.6.1. Market Revenue and Forecast
10.1.7. Head and Neck Cancer
10.1.7.1. Market Revenue and Forecast
10.1.8. Giloblastoma
10.1.8.1. Market Revenue and Forecast
10.1.9. Malignant Meningioma
10.1.9.1. Market Revenue and Forecast
10.1.10. Others
10.1.10.1. Market Revenue and Forecast
11.1. Cancer Therapeutics and Biotherapeutics Market, by Top Selling Drugs Type
11.1.1. Revlimid
11.1.1.1. Market Revenue and Forecast
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast
11.1.3. Herceptin
11.1.3.1. Market Revenue and Forecast
11.1.4. Rituxan
11.1.4.1. Market Revenue and Forecast
11.1.5. Opdivo
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product
12.1.2. Market Revenue and Forecast, by End User
12.1.3. Market Revenue and Forecast, by Application Type
12.1.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product
12.1.5.2. Market Revenue and Forecast, by End User
12.1.5.3. Market Revenue and Forecast, by Application Type
12.1.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product
12.1.6.2. Market Revenue and Forecast, by End User
12.1.6.3. Market Revenue and Forecast, by Application Type
12.1.6.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product
12.2.2. Market Revenue and Forecast, by End User
12.2.3. Market Revenue and Forecast, by Application Type
12.2.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product
12.2.5.2. Market Revenue and Forecast, by End User
12.2.5.3. Market Revenue and Forecast, by Application Type
12.2.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product
12.2.6.2. Market Revenue and Forecast, by End User
12.2.6.3. Market Revenue and Forecast, by Application Type
12.2.6.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product
12.2.7.2. Market Revenue and Forecast, by End User
12.2.7.3. Market Revenue and Forecast, by Application Type
12.2.7.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product
12.2.8.2. Market Revenue and Forecast, by End User
12.2.8.3. Market Revenue and Forecast, by Application Type
12.2.8.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product
12.3.2. Market Revenue and Forecast, by End User
12.3.3. Market Revenue and Forecast, by Application Type
12.3.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product
12.3.5.2. Market Revenue and Forecast, by End User
12.3.5.3. Market Revenue and Forecast, by Application Type
12.3.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product
12.3.6.2. Market Revenue and Forecast, by End User
12.3.6.3. Market Revenue and Forecast, by Application Type
12.3.6.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product
12.3.7.2. Market Revenue and Forecast, by End User
12.3.7.3. Market Revenue and Forecast, by Application Type
12.3.7.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product
12.3.8.2. Market Revenue and Forecast, by End User
12.3.8.3. Market Revenue and Forecast, by Application Type
12.3.8.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product
12.4.2. Market Revenue and Forecast, by End User
12.4.3. Market Revenue and Forecast, by Application Type
12.4.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product
12.4.5.2. Market Revenue and Forecast, by End User
12.4.5.3. Market Revenue and Forecast, by Application Type
12.4.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product
12.4.6.2. Market Revenue and Forecast, by End User
12.4.6.3. Market Revenue and Forecast, by Application Type
12.4.6.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product
12.4.7.2. Market Revenue and Forecast, by End User
12.4.7.3. Market Revenue and Forecast, by Application Type
12.4.7.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product
12.4.8.2. Market Revenue and Forecast, by End User
12.4.8.3. Market Revenue and Forecast, by Application Type
12.4.8.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product
12.5.2. Market Revenue and Forecast, by End User
12.5.3. Market Revenue and Forecast, by Application Type
12.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product
12.5.5.2. Market Revenue and Forecast, by End User
12.5.5.3. Market Revenue and Forecast, by Application Type
12.5.5.4. Market Revenue and Forecast, by Top Selling Drugs Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product
12.5.6.2. Market Revenue and Forecast, by End User
12.5.6.3. Market Revenue and Forecast, by Application Type
12.5.6.4. Market Revenue and Forecast, by Top Selling Drugs Type
13.1. Amgen Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bristol-Myers Squibb
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Celgene Corporation
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ELI Lilly and Company
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Hoffmann-La Roche AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. EnGeneIC Ltd
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Co Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample